Prostatic Neoplasm Clinical Trial
— BRAchySABROfficial title:
High-Dose-Rate Prostate Brachytherapy Combined With Stereotactic Ablative Prostate Radiotherapy for Patients Diagnosed With Intermediate and High-risk Prostate Cancer. Phase II Clinical Trial.
NCT number | NCT04523896 |
Other study ID # | BRAchySABR |
Secondary ID | |
Status | Recruiting |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | July 1, 2019 |
Est. completion date | July 2023 |
Dose escalation is nowadays a standard strategy in radiotherapy for prostate cancer. Besides,
it is believed that due to the radiobiology characteristics of prostate cells (low alpha/beta
ratio), the delivery of higher radiation doses per fraction could theoretically improve the
efficacy of the treatment. In this context, the combination of prostate brachytherapy and
external beam radiotherapy (EBRT) has proven to be the most effective method of dose
escalation significantly improving disease control in randomized clinical trials.
Unfortunately, this strategy is also associated with an increased risk of acute and late
adverse events compared to conventional EBRT alone. It has been proposed that this increase
in adverse events could be related to the use Low-Dose-Rate (LDR) brachytherapy and that
High-Dose-Rate (HDR) brachytherapy (a more modern and accurate procedure) could reduce this
risk.
On the other hand, Stereotactic Ablative Radiotherapy (SABR) is a high-precision radiation
technique that allows the delivery of higher doses per fraction in fewer sessions, reducing
the total treatment time.
The investigators hypothesized that the combination of two highly conformal radiation
techniques (HDR brachytherapy and SABR) could be well tolerated, while reducing total
treatment time and therefore improving patient quality of life.
This is a single arm Phase II clinical trial designed to test the feasibility, tolerability
and impact on quality of life of the combination of High-Dose-Rate prostate brachytherapy and
SABR for patients with intermediate and high-risk prostate cancer.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | July 2023 |
Est. primary completion date | July 2021 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically confirmed diagnosis of adenocarcinoma of the prostate. - Intermediate or high-risk disease (as per NCCN criteria): - Intermediate risk: - Clinical stage = T2c - Gleason score 7 and initial PSA = 20 ng/ml. - Gleason score = 6 and initial PSA > 10 and = 20 ng/ml. - High risk,at least one of the following: - Clinical stage T3a-b. - Gleason score 8-10. - Initial PSA > 20 ng/ml. - Life expectancy of more than 10 years - Able and willing to complete Expanded Prostate Index Composite (EPIC) end EORTC questionnaires - Eastern Cooperative Oncology Group (ECOG) of 0 - 2. - Willing to give informed consent to participate in this clinical trial - Give competent informed consent to participate in this trial. Exclusion Criteria: - Documented nodal or distant metastases. - Previous pelvic radiotherapy. - Clinical stage T4. - Clinical stage T3a or T3b in which the coverture of the extraprostatic disease is not feasible (as deemed by the treating physician). - Prostate volume > 70 cc (measured on MRI). - Poor baseline urinary function defined as International Prostate Symptom Score (IPSS) >17 - Contra-indication to radical prostate radiotherapy - Significant medical co-morbidity rendering patient unsuitable for general anaesthetic |
Country | Name | City | State |
---|---|---|---|
Spain | Biocruces Bizkaia Health Research Institute/Cruces University Hospital | Barakaldo | Bizkaia |
Lead Sponsor | Collaborator |
---|---|
David Büchser |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Deterioration of patient quality of life as assessed by EPIC-26 (The Expanded Prostate Cancer Index Composite short form) | Impact on Quality of life affecting the genitourinary, gastrointestinal, sexual and hormonal domains using the EPIC-26 short form (graded from 0-100, with higher scores representing better quality of life). Baseline value (i.e. prior to treatment) will be compared to values recorded 1 month, 3 months, 12 months and 24 months after treatment. | 24 months | |
Primary | Deterioration of patient quality of life as assessed by EORTC (European Organisation for Research and Treatment of Cancer) QLQ-PR25 short form. | Impact on Quality of life affecting the genitourinary, gastrointestinal, sexual and hormonal domains using the EORTC QLQ-PR25 short form (items and scale scores of the QLQ-PR25 are linearly transformed to a 0-100 scale, with higher scores reflecting either more symptoms (urinary, bowel, hormonal treatment-related symptoms) or higher levels of functioning (sexual).). Baseline value (i.e. prior to treatment) will be compared to values recorded 1 month, 3 months, 12 months and 24 months after treatment. | 24 months | |
Primary | Incidence and severity of genitourinary treatment-related acute adverse events graded according to CTCAE (Common Terminology Criteria for Adverse Events) v5.0 scale. | Every urinary event occurring within 3 months from treatment completion will be defined as "acute event". All adverse events will be recorded and graded according to CTCA V5.0 scale (graded from 0-5 with greater values representing worse outcomes) | 3 months | |
Primary | Incidence and severity of gastrointestinal treatment-related acute adverse events graded according to CTCAE (Common Terminology Criteria for Adverse Events) v5.0 scale. | Every gastrointestinal event occurring within 3 months from treatment completion will be defined as "acute event". All adverse events will be recorded and graded according to CTCA V5.0 scale (graded from 0-5 with greater values representing worse outcomes) | 3 months | |
Primary | Incidence and severity of genitourinary treatment-related late adverse events graded according to CTCAE (Common Terminology Criteria for Adverse Events) v5.0 scale. | Every genitourinary event occurring 3 months after treatment completion will be defined as "late event". All adverse events will be recorded and graded according to CTCA V5.0 scale (graded from 0-5 with greater values representing worse outcomes) 6 months, 12 months and 24 months after treatment. | 24 months months | |
Primary | Incidence and severity of gastrointestinal treatment-related late adverse events graded according to CTCAE (Common Terminology Criteria for Adverse Events) v5.0 scale. | Every gastro-intestinal event occurring 3 months after treatment completion will be defined as "late event". All adverse events will be recorded and graded according to CTCA V5.0 scale (graded from 0-5 with greater values representing worse outcomes) 6 months, 12 months and 24 months after treatment. | 24 months months | |
Secondary | Treatment efficacy in biochemical control measured through PSA (prostate specific antigen) level. | PSA will be evaluated at baseline and in every follow-up visit (1 month, 3 months, 6 months, 12 months and 24 months after treatment completion. | 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03982095 -
Survey on Lifestyle, Perceived Barriers and Development of Change in Patients With Prostate Cancer
|
||
Recruiting |
NCT05667636 -
Early Salvage Stereotactic Radiotherapy for Biochemical Failure After RP
|
Phase 2 | |
Terminated |
NCT01996696 -
Prevention of Metabolic Syndrome and Increased Weight Using Metformin Concurrent to Androgen Deprivation Therapy and Radiotherapy for Locally Advanced Adenocarcinoma of the Prostate
|
Phase 2 | |
Completed |
NCT01431391 -
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
|
Phase 2 | |
Completed |
NCT03289130 -
Dietary Factors and Racial Disparities in Prostate Cancer Aggressiveness
|
||
Recruiting |
NCT04462926 -
Evaluation of Diagnostic Accuracy of [68Ga]Ga-PSMA-11 PET/CT in Primary Staging of Intermediate and High Risk Prostatic Cancer in Men Newly Diagnosed
|
N/A | |
Completed |
NCT00001446 -
A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer
|
Phase 2 | |
Completed |
NCT02729103 -
Treatment Patterns in Metastatic Prostate Cancer
|
N/A | |
Completed |
NCT00956228 -
Study of Radioimmunoguided Intensity Modulated Radiotherapy (IMRT) for Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00247312 -
Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial
|
Phase 3 | |
Completed |
NCT00126854 -
High Field Magnetic Resonance Spectroscopy Imaging for Follow Up of Prostate Cancer Post Brachytherapy Implantation
|
N/A | |
Completed |
NCT00174863 -
Evaluation of SR 31747A Versus Placebo in Androgen-Independent Non Metastatic Prostate Cancer
|
Phase 2 | |
Terminated |
NCT04221828 -
Trial of NanoPac Focal Therapy for Prostate Cancer
|
Phase 2 | |
Completed |
NCT00001266 -
A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT03935282 -
Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors
|
N/A | |
Completed |
NCT03693742 -
MSG Use With 18F-DCFPyL PET/CT Imaging
|
N/A | |
Recruiting |
NCT06236789 -
Observation Study to Evaluate the Efficacy and Safety of Ifosfamide/Mesna in Patients With Metastatic Castration-resistant Prostate Cancer
|
||
Completed |
NCT02966535 -
The Effect of Prolonged Inspiratory Time on Gas Exchange During Robot-assisted Laparoscopic Surgery With Steep Trendelenburg Position : A Crossover Randomized Clinical Trial
|
N/A | |
Completed |
NCT02977143 -
Positive End-expiratory Pressure-induced Increase in Central Venous Pressure as a Predictor of Fluid Responsiveness in Robot-assisted Laparoscopic Surgery
|
N/A | |
Completed |
NCT00252460 -
CT/MRI Co-registration Prostate Cancer
|
Phase 1 |